fbpx The tip of the iceberg | Progress In Mind

The tip of the iceberg

Psychiatric congress
Two big screen in congress

Al simposio EPA 2017 sui disturbi dello spettro autistico, sono stati presentati i più recenti approcci per entrare nella neurobiologia di questo complesso disturbo.

Psychotic-like experiences in autism


Dr Marinos Kyriakopoulos, King’s College London, highlighted the clinical and cognitive overlaps between autism spectrum disorders (ASD) and schizophrenia, as well as some common neurobiological characteristics.

Historically, autism and schizophrenia were considered to be related diagnostic entities. In 1911, Bleuler described ‘autism’ as a symptom of schizophrenia. In 1980, autism and schizophrenia were separated into different diagnostic categories in DSM-III. In the fact, the term ‘autism spectrum disorders’ is fairly new - coined by Allen in 1988 (Pina Camacho 2016).

The term ‘autism spectrum disorders’ is fairly new.

Dr Kyriakopoulos described the overlapping features of phenomenology between ASD and schizophrenia - including flattened affect, psychomotor abnormalities, and deficits in higher-order social cognition. ASD and schizophrenia also show common cognitive deficits.

He presented a study of the first empirically derived classification of children with ASD in relation to psychosis, based on three underlying symptom dimensions - anxiety, social deficits and thought disorder. These dimensions are included in the Multiple Complex Developmental Disorder Research criteria. In an in-patient sample of children, both ASD and psychotic-like ASD groups were identified. Hallucinations were only experienced in the psychotic-like ASD group (11/43 children, 26%). His data show that 70% of children with psychotic symptoms go on to receive a diagnosis of ASD. The clinical boundaries and overlapping pathophysiology of ASD and psychosis are clearly relevant.


Iceberg ahead!


Prof Tanja Sheldrick-Michel, University of Southern Denmark, described ASD as an iceberg: we see in part, but most remains hidden. She pointed to the importance of neurobiology. To treat effectively, we need to understand the underlying mechanisms. This also helps to destigmatize mental health. Multidimensional research strategies may have a lot to offer, Prof Sheldrick-Michel told us.

Described ASD as an iceberg: we see in part, but most remains hidden.


Building bridges


Prof Sheldrick-Michel introduced us to Brain Research InterDisciplinary Guided Excellence (BRIDGE) - which aims to close the gap between clinical expertise and science. Using patient cohorts’ biobanking, ‘multi-OMICS’ and imaging to generate big data, it is envisioned that disease-specific multi-dimensional biomarkers could be identified. This would allow us to identify patients, individualize treatment, prevent and even cure.


Autism and depression - a common neurobiology


In Denmark, cohorts show significant comorbidity with depression in adults with ASD. Prof Sheldrick-Michel suggested that there may be a common neurobiology of autism and depression - perhaps due to oxidative stress and neurotrophic factors.




The tin-man in the Wizard of OZ, who laments ‘if only I had a heart’, reminds Prof Sheldrick-Michel of many of her patients with ASD. They want to feel, but struggle to understand the emotions of others. She has identified neuronal correlates of impaired perspective taking and emotion recognition - particularly hyperactivation in patients’ cortico-limbic system. When recognizing emotions, patients with ASD have to think harder and longer, and use different parts of the brain compared to healthy controls.


Brain organoids


Prof Sheldrick-Michel is using brain organoids - derived from patients’ induced pluripotent stem cells - as relevant cellular in vitro platforms to investigate the mechanisms of ADS pathology. Studying these ‘mini brains’ at different time points in their development will give us a picture of the disease dynamic, she explained. This exciting approach may open the door to personalized medicine in this field.


Different trajectories in brain development


Prof Paolo Brambilla, University of Milan, Italy, described recent findings in developmental connectivity in children with ASD. Voxel-based morphometry and diffusion weighted imaging were used to study 20 children with ASD, and 20 typically developing children. This study showed that in ASD there is fronto-parietal dysconnectivity and an altered trajectory of white matter maturation. He proposed that these may be potential neurodevelopmental markers of ASD.

A study of gray matter correlates of language development in 28 children with ASD suggested a coupling between gray matter parietal volume and delayed language, as well as white matter parietal volume and motor development.

These studies point to atypical brain maturation in ASD.

In a recent study, Prof Brambilla and colleagues looked into gray matter morphology in ASD. This study included 211 children with ASD, and 143 healthy controls. The preliminary results suggest a key role of the insular cortex during maturation. This may be the cause of altered emotional processing in ASD. They also saw altered maturation of the left orbitofrontal cortex, higher intracranial volume in early childhood, and slower intracranial volume maturation rate.

All these studies point to atypical brain maturation in ASD. There appears to be altered connectivity between the corpus callosum, temporo-parietal cortex, and the limbic system. Prof Brambilla urged that future longitudinal studies should investigate the brain connectivity trajectory as it relates to social, cognitive and language deficits.

Our correspondent’s highlights from the symposium are meant as a fair representation of the scientific content presented. The views and opinions expressed on this page do not necessarily reflect those of Lundbeck.

You are leaving Progress in Mind
Le informazioni contenute nel nuovo sito prescelto possono non essere conformi al D.Ivo 219/06 che regola la pubblicità dei medicinali per uso umano e le opinioni espresse non riflettono necessariamente le posizioni dell’azienda, non sono da essa avvallate.
Accesso riservato a Operatori Sanitari
Per accedere si prega di registrarsi o, in caso sia già stato fatto, di autenticarsi
L’accesso a Progress in Mind Italia è consentito unicamente ai Professionisti Sanitari. I contenuti di questo sito sono prodotti da un team dedicato di Professionisti Sanitari e medical writer il cui obiettivo è presentare le novità scientifiche più recenti insieme ad opinioni di esperti ed approfondimenti in ambito psichiatrico e neurologico. Per poter accedere al sito è, quindi, necessario registrarsi e fornire alcuni dati così da poter verificare che l‘utente sia un Professionista Sanitario.
Per accedere alla pagina si prega di registrarsi o, in caso sia già stato fatto, di autenticarsi. La pagina per la quale sta richiedendo l'accesso ospita materiale formativo comunque attinente all'impiego di medicinali prodotti o commercializzati da Lundbeck. Con riferimento al Decreto Legislativo n.219 del 24 aprile 2006 e s.m.i., art. 119, art. 121 comma 1 e art. 124 commi 4 e 8, Lundbeck limita l'accesso ai contenuti presenti nella pagina PIM Academy a medici specialisti e farmacisti ospedalieri.
Please confirm your email
We have just sent you an email, with a confirmation link.
Before you can gain full access - you need to confirm your email.
The information on this site is exclusively intented for health care professionals.
All the information included in the Website is related to products of the local market and, therefore, directed to health professionals legally authorized to prescribe or dispense medications with professional practice. The technical information of the drugs is provided merely informative, being the responsibility of the professionals authorized to prescribe drugs and decide, in each concrete case, the most appropriate treatment to the needs of the patient.
Register for access to Progress in Mind in your country